Bortezomib in combination with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma: evaluation of efficacy and safety in real clinical practice
Multiple myeloma (MM) is a common hematological malignancy. The high efficacy of the VTD induction regimen (bortezomib, thalidomide, dexamethasone) is limited by dose-dependent adverse reactions of thalidomide. Objective. To evaluate the effect of a thalidomide dose-escalation strategy in the VTD regimen on efficac...